Revisión web de pharmaphorum.com
pharmaphorum | News & views on pharma and biotech’s evolving future
Generado el 06 Marzo 2026 13:56 PM
Resultados antiguos? ACTUALIZAR !
La puntuación es 56/100
Contenido SEO
Título
pharmaphorum | News & views on pharma and biotech’s evolving future
Longitud : 67
Perfecto, tu título contiene entre 10 y 70 caracteres.
Descripción
pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future.
Longitud : 158
Genial, tu descripción meta contiene entre 70 y 160 caracteres.
Palabras Claves (Keywords)
Muy mal. No hemos encontrado palabras clave (meta keywords) en tu página. Usa este generador de meta tags gratuito para crear tus palabras clave.
Propiedades Meta Og
Bien. Tu página usa propiedades Og (etiquetas og).
| Propiedad | Contenido |
|---|---|
| site_name | pharmaphorum |
| url | https://pharmaphorum.com/homepage |
| title | pharmaphorum| News & views on pharma and biotech’s evolving future |
| description | Pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future. |
Titulos
| H1 | H2 | H3 | H4 | H5 | H6 |
| 0 | 7 | 37 | 0 | 12 | 0 |
- [H2] Featured Content
- [H2] Latest News
- [H2] Views & Analysis
- [H2] Deep Dive
- [H2] White Papers & Webinar
- [H2] Podcasts & Video
- [H2] Partner Content
- [H3] China's clears Pfizer GLP-1 ecnoglutide for weight loss
- [H3] J&J's Tecvayli claims third national priority FDA approval
- [H3] The GLP-1 Reckoning
- [H3] Alnylam bets on Tenaya RNAi tech, and other licensing news
- [H3] What US healthcare companies and medical researchers need to...
- [H3] What US healthcare companies and medical researchers need to...
- [H3] The GLP-1 Reckoning
- [H3] Using AI-driven synthetic personas to take your insights fur...
- [H3] AI in clinical development & ‘white space’, with Andrew Mack...
- [H3] New hope for ovarian cancer, with Alexander Schneider
- [H3] Expert Directed Applied Intelligence: Redefining AI in Life ...
- [H3] Editor's Picks
- [H3] China's clears Pfizer GLP-1 ecnoglutide for weight loss
- [H3] J&J's Tecvayli claims third national priority FDA approval
- [H3] Alnylam bets on Tenaya RNAi tech, and other licensing news
- [H3] Lilly unveils employer scheme for weight-loss drug Zepbound
- [H3] What US healthcare companies and medical researchers need to...
- [H3] JPM 2026: What it revealed about biotech’s new reality
- [H3] Pharma’s search loophole is a preview of what comes next
- [H3] Legacy data into living scientific memory
- [H3] The GLP-1 Reckoning
- [H3] GLP-1s: Five years that changed metabolic medicine
- [H3] Redesigning obesity trials for a chronic disease era
- [H3] The trust gap: GLP-1s and the new information economy of obe...
- [H3] Using AI-driven synthetic personas to take your insights fur...
- [H3] Expert Directed Applied Intelligence: Redefining AI in Life ...
- [H3] The strategic imperative of Integrated Evidence Generation P...
- [H3] Data managers and CRAs warn of rising data quality risks due...
- [H3] AI in clinical development & ‘white space’, with Andrew Mack...
- [H3] Collaboration & personalisation in rare disease R&D, with AO...
- [H3] Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...
- [H3] On JPM2026 and healthcare investment today, with Jonah Comst...
- [H3] 7th Dermatology Drug Development Summit Europe
- [H3] The PM Society Launches Pharmony to Support More Effective P...
- [H3] EVERSANA Names Monica Avram Executive Vice President and Chi...
- [H3] Emerging Trends in Personalised Medicine at PHARMAP 2026
- [H3] Book your tickets and join the PM Society for the 40th PM Aw...
- [H5] header links
- [H5] Pharmaphorum menu first category
- [H5] SECTION
- [H5] Channels
- [H5] Channels
- [H5] SUB NAVIGATION
- [H5] US lawmakers take FDA to task over rare diseases record
- [H5] Gilead buys cell therapy partner Arcellx for up to $7.8bn
- [H5] What next for pharma as SCOTUS strikes down Trump tariffs?
- [H5] Novo Nordisk to cut GLP-1 prices in tough US market
- [H5] UK spurs prescribing of obesity jab Mounjaro with GP bonus
- [H5] Pharmaphorum Menu
Imagenes
Hemos encontrado 42 imágenes en esta web.
Bien, la mayoría de tus imágenes tienen atributo alt.
Ratio Texto/HTML
Ratio : 18%
Bien, el ratio entre texto y código HTML de esta página es mayor que 15, pero menor que 25 por ciento.
Flash
Perfecto, no se ha detectado contenido Flash en la página.
Iframe
Muy mal, tienes Iframes en la página, esto significa que el contenido no podrá ser indexado.
Enlaces SEO
Reescritura URL
Bien. Tus enlaces parecen amigables
Guiones bajos en las URLs
Hemos detectado guiones bajos en tus URLs. Deberías usar guiones en su lugar para optimizar tu SEO.
Enlaces en página
Hemos encontrado un total de 136 enlaces incluyendo 1 enlace(s) a ficheros
| Ancla | Tipo | Jugo |
|---|---|---|
| Skip to main content | Interna | Pasando Jugo |
| BlueSky | Externo | Pasando Jugo |
| Externo | Pasando Jugo | |
| youtube | Externo | Pasando Jugo |
| Get Newsletters | Interna | Pasando Jugo |
| Media Kit | Interna | Pasando Jugo |
| News | Interna | Pasando Jugo |
| Views & Analysis | Interna | Pasando Jugo |
| Deep Dive | Interna | Pasando Jugo |
| Equity and Sustainability | Interna | Pasando Jugo |
| Research & Development | Interna | Pasando Jugo |
| Market Access | Interna | Pasando Jugo |
| Oncology | Interna | Pasando Jugo |
| Artificial Intelligence | Interna | Pasando Jugo |
| Patients & Partnerships | Interna | Pasando Jugo |
| GLP-1 | Interna | Pasando Jugo |
| Previous Editions | Interna | Pasando Jugo |
| Webinars | Interna | Pasando Jugo |
| Podcasts | Interna | Pasando Jugo |
| Videos | Interna | Pasando Jugo |
| Spotlight on | Interna | Pasando Jugo |
| ASCO 2025 | Interna | Pasando Jugo |
| BIO 2025 | Interna | Pasando Jugo |
| C-Suite Innovators | Interna | Pasando Jugo |
| ESMO 2025 | Interna | Pasando Jugo |
| Frontiers Health 2025 | Interna | Pasando Jugo |
| JP Morgan | Interna | Pasando Jugo |
| Global Policy Insights | Interna | Pasando Jugo |
| Events | Interna | Pasando Jugo |
| close | Externo | Pasando Jugo |
| Market Access | Interna | Pasando Jugo |
| Oncology | Interna | Pasando Jugo |
| Patients & Partnerships | Interna | Pasando Jugo |
| Commercialisation | Interna | Pasando Jugo |
| White Papers | Interna | Pasando Jugo |
| Sales & Marketing | Interna | Pasando Jugo |
| R&D | Interna | Pasando Jugo |
| Digital | Interna | Pasando Jugo |
| Market Access | Interna | Pasando Jugo |
| Oncology | Interna | Pasando Jugo |
| Patients | Interna | Pasando Jugo |
| Live Coverage | Interna | Pasando Jugo |
| Partner Content | Interna | Pasando Jugo |
| About us | Interna | Pasando Jugo |
| Contribute | Interna | Pasando Jugo |
| Contact us | Interna | Pasando Jugo |
| Sign in | Interna | Pasando Jugo |
| China's clears Pfizer GLP-1 ecnoglutide for weight loss | Interna | Pasando Jugo |
| J&J's Tecvayli claims third national priority FDA approval | Interna | Pasando Jugo |
| The GLP-1 Reckoning | Interna | Pasando Jugo |
| Alnylam bets on Tenaya RNAi tech, and other licensing news | Interna | Pasando Jugo |
| What US healthcare companies and medical researchers need to... | Interna | Pasando Jugo |
| Using AI-driven synthetic personas to take your insights fur... | Interna | Pasando Jugo |
| AI in clinical development & ‘white space’, with Andrew Mack... | Interna | Pasando Jugo |
| New hope for ovarian cancer, with Alexander Schneider | Interna | Pasando Jugo |
| Expert Directed Applied Intelligence: Redefining AI in Life ... | Interna | Pasando Jugo |
| US lawmakers take FDA to task over rare diseases record | Interna | Pasando Jugo |
| Gilead buys cell therapy partner Arcellx for up to $7.8bn | Interna | Pasando Jugo |
| What next for pharma as SCOTUS strikes down Trump tariffs? | Interna | Pasando Jugo |
| Novo Nordisk to cut GLP-1 prices in tough US market | Interna | Pasando Jugo |
| UK spurs prescribing of obesity jab Mounjaro with GP bonus | Interna | Pasando Jugo |
| Subscribe | Interna | Pasando Jugo |
| Lilly unveils employer scheme for weight-loss drug Zepbound | Interna | Pasando Jugo |
| JPM 2026: What it revealed about biotech’s new reality | Interna | Pasando Jugo |
| Pharma’s search loophole is a preview of what comes next | Interna | Pasando Jugo |
| Legacy data into living scientific memory | Interna | Pasando Jugo |
| GLP-1s: Five years that changed metabolic medicine | Interna | Pasando Jugo |
| Redesigning obesity trials for a chronic disease era | Interna | Pasando Jugo |
| The trust gap: GLP-1s and the new information economy of obe... | Interna | Pasando Jugo |
| The strategic imperative of Integrated Evidence Generation P... | Interna | Pasando Jugo |
| Data managers and CRAs warn of rising data quality risks due... | Interna | Pasando Jugo |
| Collaboration & personalisation in rare disease R&D, with AO... | Interna | Pasando Jugo |
| Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al... | Interna | Pasando Jugo |
| On JPM2026 and healthcare investment today, with Jonah Comst... | Interna | Pasando Jugo |
| 7th Dermatology Drug Development Summit Europe | Interna | Pasando Jugo |
| The PM Society Launches Pharmony to Support More Effective P... | Interna | Pasando Jugo |
| EVERSANA Names Monica Avram Executive Vice President and Chi... | Interna | Pasando Jugo |
| Emerging Trends in Personalised Medicine at PHARMAP 2026 | Interna | Pasando Jugo |
| Book your tickets and join the PM Society for the 40th PM Aw... | Interna | Pasando Jugo |
| News | Interna | Pasando Jugo |
| Views & Analysis | Interna | Pasando Jugo |
| Deep Dive | Interna | Pasando Jugo |
| Webinars | Interna | Pasando Jugo |
| Podcasts | Interna | Pasando Jugo |
| Video | Interna | Pasando Jugo |
| White Papers | Interna | Pasando Jugo |
| Event | Interna | Pasando Jugo |
| News | Interna | Pasando Jugo |
| Views & Analysis | Interna | Pasando Jugo |
| Deep Dive | Interna | Pasando Jugo |
| Webinars | Interna | Pasando Jugo |
| Podcasts | Interna | Pasando Jugo |
| Video | Interna | Pasando Jugo |
| White Papers | Interna | Pasando Jugo |
| Event | Interna | Pasando Jugo |
| News | Interna | Pasando Jugo |
| Views & Analysis | Interna | Pasando Jugo |
| Deep Dive | Interna | Pasando Jugo |
| Webinars | Interna | Pasando Jugo |
| Podcasts | Interna | Pasando Jugo |
| Video | Interna | Pasando Jugo |
| White Papers | Interna | Pasando Jugo |
| Event | Interna | Pasando Jugo |
| News | Interna | Pasando Jugo |
| Views & Analysis | Interna | Pasando Jugo |
| Deep Dive | Interna | Pasando Jugo |
| Webinars | Interna | Pasando Jugo |
| Podcasts | Interna | Pasando Jugo |
| Video | Interna | Pasando Jugo |
| White Papers | Interna | Pasando Jugo |
| Event | Interna | Pasando Jugo |
| News | Interna | Pasando Jugo |
| Views & Analysis | Interna | Pasando Jugo |
| Deep Dive | Interna | Pasando Jugo |
| Webinars | Interna | Pasando Jugo |
| Podcasts | Interna | Pasando Jugo |
| Video | Interna | Pasando Jugo |
| White Papers | Interna | Pasando Jugo |
| Event | Interna | Pasando Jugo |
| News | Interna | Pasando Jugo |
| Views & Analysis | Interna | Pasando Jugo |
| Deep Dive | Interna | Pasando Jugo |
| Webinars | Interna | Pasando Jugo |
| Podcasts | Interna | Pasando Jugo |
| Video | Interna | Pasando Jugo |
| White Papers | Interna | Pasando Jugo |
| Event | Interna | Pasando Jugo |
| Axtria Ignite 2025 | Interna | Pasando Jugo |
| Frontiers Health 2024 | Interna | Pasando Jugo |
| Life Science Industry Report | Interna | Pasando Jugo |
| World Without Disease Summit | Interna | Pasando Jugo |
| Pharmaphorum | Interna | Pasando Jugo |
| Cookie Policy | Interna | Pasando Jugo |
| Privacy Policy | Interna | Pasando Jugo |
| Terms & Conditions | Interna | Pasando Jugo |
| Work for us | Interna | Pasando Jugo |
Palabras Clave SEO
Nube de Palabras Clave
sponsored content event healthcare news digital pharmaphorum dive white glp-1
Consistencia de las Palabras Clave
| Palabra Clave (Keyword) | Contenido | Título | Palabras Claves (Keywords) | Descripción | Titulos |
|---|---|---|---|---|---|
| news | 17 |  |
 |
|
|
| white | 11 | |
|
|
|
| event | 10 | |
|
|
|
| healthcare | 9 | |
|
|
|
| content | 9 | |
|
|
|
Usabilidad
Url
Dominio : pharmaphorum.com
Longitud : 16
Favicon
Genial, tu web tiene un favicon.
Imprimibilidad
No hemos encontrado una hoja de estilos CSS para impresión.
Idioma
Genial. Has declarado el idioma en.
Dublin Core
Esta página no usa Dublin Core.
Documento
Tipo de documento (Doctype)
HTML 5
Codificación
Perfecto. Has declarado como codificación UTF-8.
Validez W3C
Errores : 0
Avisos : 0
Privacidad de los Emails
Genial. No hay ninguna dirección de email como texto plano!
HTML obsoleto
Genial, no hemos detectado ninguna etiqueta HTML obsoleta.
Consejos de Velocidad
|
Excelente, esta web no usa tablas. |
|
Muy mal, tu web está usando estilos embenidos (inline CSS). |
|
Genial, tu página web usa muy pocos ficheros CSS. |
|
Muy mal, tu sitio usa demasiados ficheros JavaScript (más de 6). |
|
Su sitio web se beneficia del tipo de compresión gzip. ¡Perfecto! |
Movil
Optimización Móvil
|
Icono para Apple |
|
Etiqueta Meta Viewport |
|
Contenido Flash |
Optimización
Mapa del sitio XML
¡Perfecto! Su sitio tiene un mapa del sitio en XML.
| https://pharmaphorum.com/sitemap.xml |
Robots.txt
https://pharmaphorum.com/robots.txt
¡Estupendo! Su sitio web tiene un archivo robots.txt.
Herramientas de Analítica
¡Perfecto! Su sitio web tiene una herramienta de análisis.
Google Analytics |
PageSpeed Insights
Dispositivo
Categorias
Free SEO Testing Tool
Free SEO Testing Tool es una herramienta seo gratuita que te ayuda a analizar tu web